| Providing patients and consumers greater access to safe and effective medicines is a public health priority for the U.S. Food and Drug Administration. The FDA's Office of Generic Drugs (OGD) has a mission to help ensure high-quality, affordable generic drugs are readily available. Currently 90% of all prescriptions dispensed in the U.S. are for generic drugs. To support the availability of generic drugs, the generic drug program approves safe, effective, high-quality drugs and monitors those drugs once they are on the market. 2021 was another successful and productive year in pursuit of this mission and the OGD annual report, published today, captures these achievements. The FDA's generic drug program approved hundreds of generic drug applications, known as abbreviated new drug applications (ANDAs), and thousands of supplements to already approved ANDAs. The FDA prioritized the assessment of generic drug application submissions for drugs identified as potential treatments and supportive therapies for patients with COVID-19. COVID-19 related submissions included more than 75 original ANDAs, some which we approved in record time, as well as more than 1,200 supplemental applications. We funded approximately $20 million in generic drug science and research programs. | | | |
No comments:
Post a Comment